Dr Laura Trotta gives us an insight into her role at CluePoints and shares some of the lessons she’s learned so far
Could you provide an overview of your role?
As the VP Research Operations & Statistical Innovation at CluePoints, I lead a dedicated team of research scientists focused on developing cutting-edge statistical and machine learning (ML) algorithms to ensure the quality of clinical trial data.
It’s incredibly rewarding to empower the team to adopt a scientific approach to ML. CluePoints remain at the forefront of this field, constantly innovating new methods to train, test, and refine solutions.
Our work integrates advanced statistical algorithms and deep learning (DL) technologies to revolutionise how clinical trials are conducted, enabling unprecedented insights from clinical data.
When did you discover your interest in science?
I’ve always been fascinated by science. Initially, my interest centered on physics—I was captivated by the mysteries of space and natural phenomena.
Discovering that mathematical equations could describe these processes was a revelation for me.
Later, at the age of 16, a biology class ignited my passion for medicine and health sciences, setting me on my current path.
Could you walk us through your journey to where you are today?
My academic background is in biomedical engineering, complemented by a PhD in applied mathematics.
From the start, I’ve been eager to leverage mathematical and technical expertise to advance medical innovation.
Before joining CluePoints, I worked as a project manager for a company specialising in 3D software solutions for medical devices.
When I began at CluePoints in 2015, I was the sole research scientist, tasked with developing algorithms to enhance the company’s statistical engine.
These algorithms remain the foundation of CluePoints’ Monitoring Platform, widely used by Sponsors, CROs, and Clinical Technology Organisations for Risk-Based Quality Monitoring (RBQM).
Over the years, our research team has grown significantly, incorporating machine learning, business intelligence, and data visualisation capabilities.
Transitioning from research roles to management, I assumed the position of VP of Research in 2022.
What challenges have you encountered, and what valuable lessons have you learned?
As a VP, facilitating effective communication among diverse stakeholders is both a challenge and an opportunity.
My engineering background equips me with the technical knowledge, my PhD sharpens my scientific acumen, and my industry experience offers practical insights into clinical trials.
I’ve learned to view challenges as opportunities for growth.
When things don’t go as planned, there’s always a lesson to carry forward.
Reflecting on what can be improved ensures continuous development.
What drives your passion in your current role?
I was drawn to CluePoints not only for its research but also for its culture of innovation, people-centered solutions, and collaboration.
We continuously develop new products to address both current and future industry challenges.
For instance, while the world is now buzzing about AI advancements, CluePoints had already committed to deep learning long ago, enabling us to stay ahead of the curve.
A recent innovation includes our medical coding solution that uses large language models to map adverse events and drugs to MedDRA and WHODrug dictionaries.
We’re also expanding our algorithms to enhance risk detection in audit trail reviews and advancing DL solutions for RBQM and clinical development.
Collaboration with industry partners and the use of agile methods enable us to gather feedback rapidly, fostering a constant cycle of improvement.
It’s incredibly fulfilling to see the tangible impact of our innovations.
For example, Pfizer implemented our agile RBQM approach during its pivotal COVID-19 vaccine trial, achieving regulatory approval for the BNT162b2 mRNA vaccine just 266 days after the World Health Organization declared the pandemic.
What is your approach to work and leadership?
I strive to cultivate a diverse and inclusive work environment.
Inspired by mentors who encouraged my growth, I mirror that supportive ethos in my management style.
This industry thrives on collaboration, and I see myself as an enabler—providing the resources and environment for my team to succeed.
My success is measured by their achievements. Today, I’m proud to lead a talented team that continuously grows while driving broader innovation.
What advice would you share with aspiring women in science?
I’ve always pursued what genuinely interests me, and I advise others to do the same. Whether it’s algorithm development or business strategy, identifying your strengths and interests is essential.
Seek out mentors who inspire and motivate you to excel, irrespective of gender.
When hiring at CluePoints, we prioritise technical expertise but equally value individuals eager to learn, collaborate, and share ideas.
For those considering a career in science, I encourage curiosity, openness to new ideas, and joining teams that support your growth.
Dr Laura Trotta joined CluePoints in 2015 and moved into her current role as Vice President of Research in January 2022, where she leads a team of research scientists responsible for developing new statistical and machine learning algorithms to assess the quality of clinical trial data.
Laura holds a Master’s degree in Biomedical Engineering and a PhD in Applied Mathematics from the University of Liège, Belgium.
link